Skip to main content

David Charles Montefiori, PhD

Professor of Surgery
Office: Surgical Oncology Res Fac, Durham, NC 27710
Campus Mail: DUMC Box 2926 Med Ctr, Durham, NC 27710

Dr. Montefiori is Professor and Director of the Laboratory for AIDS Vaccine Research and Development in the Department of Surgery, Division of Surgical Sciences, Duke University Medical Center. His major research interests are viral immunology and AIDS vaccine development, with a special emphasis on neutralizing antibodies. One of his highest priorities is to identify immunogens that generate broadly cross-reactive neutralizing antibodies for inclusion in HIV vaccines.  Many aspects of the neutralizing antibody response are studied in his laboratory, including mechanisms of neutralization and escape, epitope diversity among genetic subtypes and geographic origins, ontogeny of broadly neutralizing antibody responses and computationally-assisted vaccine design. Over the years he has explored multiple types of assays for neutralizing antibodies and other potential antiviral antibodies, focusing on assay optimization, standardization, validation and high throughput. The scope of research covers HIV-infected individuals and nonhuman primate models of simian immunodeficiency virus (SIV) and simian-human immunodeficiency virus (SHIV) infection.  Dr. Montefiori also directs a large AIDS vaccine immune monitoring program, which operates in compliance with Good Clinical Laboratory Practice and has served as a national and international resource for standardized assessments of neutralizing antibody responses in preclinical and clinical trials of candidate AIDS vaccines since 1988. In 2002 he chaired the Antibody Laboratory Standardization Working Group that assisted in the design of the Global HIV Vaccine Enterprise Strategic Plan for HIV vaccines. He currently directs the Core Neutralizing Antibody Laboratories for the HIV Vaccine Clinical Trials Network (HVTN), the NIH Preclinical HIV-1 Vaccine Program and the Center for HIV/AIDS Vaccine Immunology- Immunogen Design (CHAVI-ID). He also directs a large Comprehensive Antibody Vaccine Immune Monitoring Consortium (CAVIMC) as part of the Bill and Melinda Gates Foundation's Collaboration for AIDS Vaccine Discovery (CAVD). He has published over 500 original research papers that have helped shape the scientific rationale for antibody-based HIV-1 vaccines.

Education and Training

  • Ph.D., Clemson University, 1982

Publications

Ringe, Rajesh P., Victor M. Cruz Portillo, Pia Dosenovic, Thomas J. Ketas, Gabriel Ozorowski, Bartek Nogal, Lautaro Perez, et al. “Neutralizing Antibody Induction by HIV-1 Envelope Glycoprotein SOSIP Trimers on Iron Oxide Nanoparticles May Be Impaired by Mannose Binding Lectin.” J Virol 94, no. 6 (February 28, 2020). https://doi.org/10.1128/JVI.01883-19.

Full Text

Bradley, Todd, Masayuki Kuraoka, Chen-Hao Yeh, Ming Tian, Huan Chen, Derek W. Cain, Xuejun Chen, et al. “Immune checkpoint modulation enhances HIV-1 antibody induction.” Nat Commun 11, no. 1 (February 19, 2020): 948. https://doi.org/10.1038/s41467-020-14670-w.

Full Text

Wise, Megan C., Ziyang Xu, Edgar Tello-Ruiz, Charles Beck, Aspen Trautz, Ami Patel, Sarah Tc Elliott, et al. “In vivo delivery of synthetic DNA-encoded antibodies induces broad HIV-1-neutralizing activity.” J Clin Invest 130, no. 2 (February 3, 2020): 827–37. https://doi.org/10.1172/JCI132779.

Full Text

Laher, Fatima, Zoe Moodie, Kristen W. Cohen, Nicole Grunenberg, Linda-Gail Bekker, Mary Allen, Nicole Frahm, et al. “Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines.” Plos Med 17, no. 2 (February 2020): e1003038. https://doi.org/10.1371/journal.pmed.1003038.

Full Text

Easterhoff, David, Justin Pollara, Kan Luo, William D. Tolbert, Brianna Young, Dieter Mielke, Shalini Jha, et al. “Boosting with AIDSVAX B/E Enhances Env Constant Region 1 and 2 Antibody-Dependent Cellular Cytotoxicity Breadth and Potency.” J Virol 94, no. 4 (January 31, 2020). https://doi.org/10.1128/JVI.01120-19.

Full Text

Giel-Moloney, M., M. Esteban, B. H. Oakes, M. Vaine, B. Asbach, R. Wagner, G. J. Mize, et al. “Recombinant HIV-1 vaccine candidates based on replication-defective flavivirus vector.” Sci Rep 9, no. 1 (December 27, 2019): 20005. https://doi.org/10.1038/s41598-019-56550-4.

Full Text

Saunders, Kevin O., Kevin Wiehe, Ming Tian, Priyamvada Acharya, Todd Bradley, S Munir Alam, Eden P. Go, et al. “Targeted selection of HIV-specific antibody mutations by engineering B cell maturation.” Science 366, no. 6470 (December 6, 2019). https://doi.org/10.1126/science.aay7199.

Full Text

Parks, K Rachael, Anna J. MacCamy, Josephine Trichka, Matthew Gray, Connor Weidle, Andrew J. Borst, Arineh Khechaduri, et al. “Overcoming Steric Restrictions of VRC01 HIV-1 Neutralizing Antibodies through Immunization.” Cell Rep 29, no. 10 (December 3, 2019): 3060-3072.e7. https://doi.org/10.1016/j.celrep.2019.10.071.

Full Text

Schifanella, Luca, Susan W. Barnett, Massimiliano Bissa, Veronica Galli, Melvin N. Doster, Monica Vaccari, Georgia D. Tomaras, et al. “ALVAC-HIV B/C candidate HIV vaccine efficacy dependent on neutralization profile of challenge virus and adjuvant dose and type.” Plos Pathog 15, no. 12 (December 2019): e1008121. https://doi.org/10.1371/journal.ppat.1008121.

Full Text

Wu, Nelson R., Nathan I. Nicely, Esther M. Lee, Rachel K. Reed, Brian E. Watts, Fangping Cai, William E. Walkowicz, et al. “Cooperation between somatic mutation and germline-encoded residues enables antibody recognition of HIV-1 envelope glycans.” Plos Pathog 15, no. 12 (December 2019): e1008165. https://doi.org/10.1371/journal.ppat.1008165.

Full Text

Pages